Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) VP Robert E. Waltermire sold 1,227 shares of the firm’s stock in a transaction on Friday, February 28th. The shares were sold at an average price of $341.07, for a total value of $418,492.89. Following the completion of the transaction, the vice president now owns 3,728 shares in the company, valued at $1,271,508.96. The trade was a 24.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Madrigal Pharmaceuticals Stock Up 2.5 %
Shares of NASDAQ:MDGL opened at $321.32 on Wednesday. The business has a 50-day moving average price of $323.17 and a 200 day moving average price of $286.30. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $7.09 billion, a price-to-earnings ratio of -12.81 and a beta of -0.38. Madrigal Pharmaceuticals, Inc. has a 12-month low of $189.00 and a 12-month high of $377.46.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.32) by $1.61. The business had revenue of $103.32 million for the quarter, compared to analyst estimates of $97.81 million. Sell-side analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on MDGL
Hedge Funds Weigh In On Madrigal Pharmaceuticals
Several institutional investors have recently bought and sold shares of MDGL. William Blair Investment Management LLC acquired a new position in Madrigal Pharmaceuticals in the 4th quarter valued at about $114,717,000. Erste Asset Management GmbH acquired a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at about $49,749,000. Paulson & CO. Inc. grew its position in Madrigal Pharmaceuticals by 10.4% in the 3rd quarter. Paulson & CO. Inc. now owns 2,042,000 shares of the biopharmaceutical company’s stock valued at $433,353,000 after acquiring an additional 192,000 shares in the last quarter. Braidwell LP acquired a new position in Madrigal Pharmaceuticals in the 3rd quarter valued at about $39,010,000. Finally, Woodline Partners LP grew its position in Madrigal Pharmaceuticals by 110.2% in the 4th quarter. Woodline Partners LP now owns 309,117 shares of the biopharmaceutical company’s stock valued at $95,384,000 after acquiring an additional 162,027 shares in the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.
Further Reading
- Five stocks we like better than Madrigal Pharmaceuticals
- 3 Stocks to Consider Buying in October
- GitLab: Get In While It’s Down—Big Rebound Ahead
- 5 Top Rated Dividend Stocks to Consider
- Tesla Stock: Finding a Bottom May Take Time
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.